Cullinan Therapeutics (CGEM) vs Savara (SVRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cullinan Therapeutics (CGEM) has outperformed Savara (SVRA) over the past year, gaining 165.4% versus a gain of 42.3%. Over five years, SVRA leads with a +278.3% price change compared with -37.5% for CGEM. Savara is the larger company by market cap ($1.00 billion vs $960.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGEM | SVRA |
|---|---|---|
| Share price | $15.63 | $4.88 |
| Market cap | $960.59M | $1.00B |
| 1-day change | -3.82% | +4.95% |
| YTD return | +51.01% | -19.07% |
| 1-year return | +165.37% | +42.27% |
| 5-year return | -37.48% | +278.29% |
| EPS (TTM) | $-3.11 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.19 | $7.01 |
| 52-week low | $6.50 | $3.35 |
| Distance from 52-week high | -32.60% | -30.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +114.01% | +126.64% |
| Average volume | 871.08K | 1.82M |
| Shares outstanding | 61.46M | 205.46M |
| Employees | 109 | 70 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CGEM has outperformed SVRA by 123.1 percentage points over the past year.
About Cullinan Therapeutics
CGEM stock →Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
About Savara
SVRA stock →Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees
CGEM vs SVRA FAQ
Which is bigger, Cullinan Therapeutics or Savara?
Savara (SVRA) is larger, with a market capitalization of $1.00B compared with $960.59M for Cullinan Therapeutics (CGEM).
Which stock has performed better over the past year, CGEM or SVRA?
CGEM returned +165.37% over the past 12 months, compared with +42.27% for SVRA (price return, excluding dividends). Past performance does not predict future results.
Are Cullinan Therapeutics and Savara in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cullinan Therapeutics and Biotechnology: Pharmaceutical Preparations for Savara.